| N (%) |
---|---|
Patient Number | 969 (100.0) |
Gender | |
  Male | 591 (61.0) |
  Female | 378 (39.0) |
Age at treatment (years) | |
  Mean (SD) | 60.01 (12.11) |
  Median (min, max) | 60 (22, 96) |
Side | |
  Left (splenic flexture to rectum) | 765 (78.9) |
  Right (cecum to hepatic flexture) | 136 (14.0) |
  Transverse | 58 (6.0) |
  Unknown | 10 (1.0) |
Histology | |
  Adenocarcinoma | 938 (96.8) |
  Others | 31 (3.2) |
Grade | |
  1 | 46 (4.7) |
  2 | 738 (76.2) |
  3 | 103 (10.6) |
Undifferentiated | 6 (0.6) |
Unknown | 76 (7.8) |
Stage at diagnosisa | |
  I-III | 419 (43.2) |
  IV | 550 (56.8) |
Time interval from diagnosis date to first prescription of Cetuximab | |
  Mean months (SD) | 26.4 (15.3) |
Cetuximab combination with chemotherapy | 961 (99.2) |
Chemotherapy after end of Cetuximab | 532 (54.9Â %) |
Death | 806 (83.2) |
Follow-up (months) | |
  Mean (SD) | 12.8 (8.6) |
  Median (min, max) | 11.3 (0.1, 39.4) |